viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals boosts 2Q revenue attributed to IXINITY acquisition

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) CEO Ken d’Entremont tells Proactive its second quarter revenue rose to C$23.6 million from C$16.4 million during the same period last year, which it attributed mainly to its acquisition of IXINITY, as well as solid performances from key products.

d’Entremont says the specialty pharmaceutical company also reported that adjusted EBITDA for the period increased to C$3.0 million from C$0.5 million a year earlier, while swinging to an operating profit of C$0.6 million from a loss of $1.3 million in second quarter 2019.

Quick facts: Medexus Pharmaceuticals Inc

Price: 5.56 CAD

Market: TSX-V
Market Cap: $80.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...



Norman Broadbent secures new loan facility

Norman Broadbent PLC (LON:NBB), the executive search group, has strengthened its balance sheet with a £250,000 six-year CBILS loan. The funds can be drawn at any point before January 16 2021, with a 12 month interest-free period following drawdown, after which an interest rate of 4.75% per...

1 day, 2 hours ago

2 min read